Search Results
Mar 20, 2026, 03:15 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Mar 20, 2026, 01:13 ET Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO
MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MREO during the class period listed are encouraged
More news about: DJS Law Group LLP
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-mereo-biopharma-group-plc-of-class-action-lawsuit-and-upcoming-deadlines--mreo-302717086.htmlSOURCE
More news about: Pomerantz LLP
Mar 18, 2026, 09:05 ET LEVI & KORSINSKY, LLP: BONE MINERAL DENSITY CLAIMS CHALLENGED IN MEREO BIOPHARMA SECURITIES ACTION
March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Mereo BioPharma Group plc (NASDAQ: MREO) to a pending securities class action. The Court has set April 6, 2026 as the deadline to apply for lead plaintiff appointment.
More news about: Levi & Korsinsky, LLP
Mar 17, 2026, 16:00 ET MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026
LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Mar 17, 2026, 09:00 ET MREO Shareholder Alert: April 6, 2026 Lead Plaintiff Deadline in Mereo BioPharma Group plc Securities Class Action Lawsuit -- The Gross Law Firm
March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO).
More news about: The Gross Law Firm
Mar 16, 2026, 02:22 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025 (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Mar 12, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Mar 12, 2026, 04:27 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Mar 12, 2026, 04:19 ET Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO
MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MREO during the class period listed are encouraged
More news about: DJS Law Group LLP
Mar 11, 2026, 09:28 ET MREO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026
LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Mar 11, 2026, 09:00 ET LEVI & KORSINSKY, LLP: CEO AND CSO NAMED AS CONTROL PERSON DEFENDANTS IN MEREO BIOPHARMA SECURITIES ACTION
NEW YORK, March 11, 2026 /PRNewswire/ -- Two senior executives of Mereo BioPharma Group plc (NASDAQ: MREO) are named as individual defendants in a securities class action: Denise Scots-Knight, Chief Executive Officer and co-founder; and John A. Lewicki,
More news about: Levi & Korsinsky, LLP
Mar 10, 2026, 19:11 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025 (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Mar 10, 2026, 09:00 ET Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join - Contact The Gross Law Firm
March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO).
More news about: The Gross Law Firm
Mar 06, 2026, 08:35 ET MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026
LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Mar 06, 2026, 03:25 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025 (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Mar 05, 2026, 16:59 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Mar 04, 2026, 09:00 ET LEVI & KORSINSKY, LLP: CHRONOLOGY OF EVENTS IN THE MEREO BIOPHARMA SECURITIES CLASS ACTION
July 9, 2025: Second interim analysis fails. December 29, 2025: Both Phase 3 trials fail. Between these dates, Mereo BioPharma Group plc (NASDAQ: MREO) shareholders allege they were kept in the dark about fundamental challenges facing the setrusumab program.
More news about: Levi & Korsinsky, LLP
Mar 03, 2026, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo Lawsuit - MREO
March 3, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO).
More news about: The Gross Law Firm
Mar 02, 2026, 03:52 ET Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO
MREO ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MREO during the class period listed are encouraged
More news about: DJS Law Group LLP
Mar 02, 2026, 03:52 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Feb 27, 2026, 08:42 ET MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc ("Mereo BioPharma" or the "Company") (NASDAQ: MREO) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Feb 26, 2026, 23:03 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025 (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Feb 26, 2026, 15:17 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-mereo-biopharma-group-plc-of-class-action-lawsuit-and-upcoming-deadlines--mreo-302698869.htmlSOURCE
More news about: Pomerantz LLP
Feb 25, 2026, 09:00 ET LEVI & KORSINSKY, LLP: MEREO BIOPHARMA SECURITIES FILINGS ALLEGEDLY CONTAINED MISLEADING CLINICAL TRIAL DISCLOSURES
or omitting material information necessary to make statements not misleading. A class action pending against Mereo BioPharma Group plc (NASDAQ: MREO) invokes these provisions, alleging the Company and certain officers misled investors about the prospects for the setrusumab drug program.
More news about: Levi & Korsinsky, LLP